Zielinski, Christoph
Lang, Istvan
Beslija, Semir
Kahan, Zsuzsanna
Inbar, Moshe J
Stemmer, Salomon M
Anghel, Rodica
Vrbanec, Damir
Messinger, Diethelm
Brodowicz, Thomas
Article History
Received: 15 June 2015
Revised: 8 October 2015
Accepted: 11 November 2015
First Online: 10 December 2015
Competing interests
: CZ has received honoraria from and acted as a consultant for Roche; SB has received honoraria from and acted as a consultant for Roche, Pfizer, AbbVie, and Novartis; ZK has acted as a consultant for Roche; DV has received honoraria from Roche and Novartis and has acted as a consultant for Roche and Sanofi Aventis; DM is an employee of a contract research organisation that provides services to F. Hoffmann-La Roche; and TB has received honoraria from Amgen, Bayer, GSK, Eli Lilly, Merck, Novartis, PharmaMar, PrimeOncology, and Roche, and has acted as a consultant for Amgen, Bayer, Novartis, and PharmaMar. The remaining authors declare no conflict of interest.